Immunity to human group A rotavirus (RV), a major cause of viral gastroenteritis in infants, involves B lymphocytes that provide RV-specific antibodies. Additionally, some arguments suggest that naive B cells could be implicated in the first steps of the immune response against RV. The aim of our study was to analyze the interaction of VP6 and VP7 RV capsid proteins with human B cells depending on the immune status of the individual, i.e., naive or RV experienced. For this purpose, a two-color virus-like particle flow cytometry assay was devised to evaluate the blood B-lymphocyte reactivity to VP6 and VP7 proteins from healthy RV-exposed adults, recently infected infants, and neonates at birth. Both VP6 and VP7 interactions with B cells were mediated by surface immunoglobulins and probably by their Fab portions. VP7-reactive B lymphocytes were mainly detected from RV-experienced patients and almost exclusively in the CD27-positive memory cell fraction. Conversely, VP6-reactive B lymphocytes were detected at similar and high frequencies in adult, infant, and neonate samples. In adult samples, VP6 reacted with about 2% of the CD27-negative (CD27 neg ) naive B cells. These results demonstrated that the VP6 RV protein interacted with a large fraction of naive B lymphocytes from both adults and neonates. We propose that naive B cell-VP6 interaction might influence the strength and quality of the acquired immune response and should be considered for elaborating RV vaccine strategies.Human group A rotavirus (RV) is recognized as a leading cause of severe dehydrating diarrhea in young children. The worldwide impact of the disease has led to extensive research to develop RV vaccines (15,16,29). However, RV vaccines only partially achieve protective immunity in humans, as do natural primary exposures. The previously released Rotashield vaccine, which has been withdrawn because of adverse effects, conferred only a 60% level of protection against RV-induced diarrhea (1, 35). The bases underlying the variable efficacy of RV vaccines are unknown. Efforts remain to be made to better understand the protective mechanisms against RV for improving vaccine strategies.RV possesses a triple-layered icosahedral protein capsid, and three of the RV structural proteins (VP4, VP6, and VP7) have important antigenic properties. The intermediate-layer capsid protein VP6 mediates group and subgroup specificity, while the outer-layer proteins VP4 and VP7 mediate serotype P and serotype G specificities, respectively (20). VP6 is the most immunogenic RV protein (20, 34). VP6 does not induce neutralizing antibodies (Abs), although some VP6-specific polymeric immunoglobulins A (IgA) are protective in vivo, probably via transcytosis through epithelial cells (6, 32). VP7 is known as the major antigen inducing neutralizing Abs (20). These Abs can passively protect experimental animals from RV-induced diarrhea (26,30,31). In humans, RV-induced Abs probably play an important role in the resolution of viral infection and against reinfections, as suggest...